Switch theme
Sign up to access all valuation multiples
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
1999
17.9K+
LTM Revenue $6.7B
LTM EBITDA $1.9B
$33.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Agilent has a last 12-month revenue (LTM) of $6.7B and a last 12-month EBITDA of $1.9B.
In the most recent fiscal year, Agilent achieved revenue of $6.5B and an EBITDA of $1.9B.
Agilent expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Agilent valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.7B | XXX | $6.5B | XXX | XXX | XXX |
| Gross Profit | $3.7B | XXX | $3.5B | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 54% | XXX | XXX | XXX |
| EBITDA | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $1.8B | XXX | $1.5B | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $1.6B | XXX | $1.3B | XXX | XXX | XXX |
| Net Margin | 24% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Agilent's stock price is $112.
Agilent has current market cap of $31.8B, and EV of $33.8B.
See Agilent trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $33.8B | $31.8B | XXX | XXX | XXX | XXX | $5.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Agilent has market cap of $31.8B and EV of $33.8B.
Agilent's trades at 5.2x EV/Revenue multiple, and 17.8x EV/EBITDA.
Equity research analysts estimate Agilent's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Agilent has a P/E ratio of 20.3x.
See valuation multiples for Agilent and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $31.8B | XXX | $31.8B | XXX | XXX | XXX |
| EV (current) | $33.8B | XXX | $33.8B | XXX | XXX | XXX |
| EV/Revenue | 5.1x | XXX | 5.2x | XXX | XXX | XXX |
| EV/EBITDA | 17.4x | XXX | 17.8x | XXX | XXX | XXX |
| EV/EBIT | 19.1x | XXX | 21.9x | XXX | XXX | XXX |
| EV/Gross Profit | 9.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.3x | XXX | 23.7x | XXX | XXX | XXX |
| EV/FCF | 27.8x | XXX | 25.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAgilent's last 12 month revenue growth is 5%
Agilent's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Agilent's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Agilent's rule of X is 42% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Agilent and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | 31% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Agilent acquired XXX companies to date.
Last acquisition by Agilent was XXXXXXXX, XXXXX XXXXX XXXXXX . Agilent acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Agilent founded? | Agilent was founded in 1999. |
| Where is Agilent headquartered? | Agilent is headquartered in United States of America. |
| How many employees does Agilent have? | As of today, Agilent has 17.9K+ employees. |
| Who is the CEO of Agilent? | Agilent's CEO is Mr. Padraig McDonnell. |
| Is Agilent publicy listed? | Yes, Agilent is a public company listed on NYS. |
| What is the stock symbol of Agilent? | Agilent trades under A ticker. |
| When did Agilent go public? | Agilent went public in 1999. |
| Who are competitors of Agilent? | Similar companies to Agilent include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of Agilent? | Agilent's current market cap is $31.8B |
| What is the current revenue of Agilent? | Agilent's last 12 months revenue is $6.7B. |
| What is the current revenue growth of Agilent? | Agilent revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Agilent? | Current revenue multiple of Agilent is 5.1x. |
| Is Agilent profitable? | Yes, Agilent is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Agilent? | Agilent's last 12 months EBITDA is $1.9B. |
| What is Agilent's EBITDA margin? | Agilent's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Agilent? | Current EBITDA multiple of Agilent is 17.4x. |
| What is the current FCF of Agilent? | Agilent's last 12 months FCF is $1.2B. |
| What is Agilent's FCF margin? | Agilent's last 12 months FCF margin is 18%. |
| What is the current EV/FCF multiple of Agilent? | Current FCF multiple of Agilent is 27.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
